Imaging, biodistribution and in vitro study of smart 99mTc-PAMAM G4 dendrimer as novel nano-complex

Narmani, Asghar; Yavari, Kamal; Mohammadnejad, Javad

doi:10.1016/j.colsurfb.2017.07.089

Cited by 64 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polyamidoamine (PAMAM) is one of the most studied dendrimers as the DDS (Figure ). PAMAM NPs are nanosized (1–10 nm), three‐dimensional, highly branched macromolecules which are consisting of three distinct components: a core, a hyperbranched mantle, and terminal functional groups (Narmani et al, ). These NPs are extremely soluble in water with many reactive end amine groups that make it as excellent nanocarrier for diagnostic and therapeutic goals (Narmani, Kamali, Amini, Salimi, & Panahi, ; Xie et al, ).…”

Section: Polymer‐based Nps In Drug Deliverymentioning

confidence: 99%

“…These results significantly support the extended residence time and control release profile of encapsulated drug in PAMAM as compared to free DOX in body (Xu et al, ). In another study, Narmani, Yavari, and Mohammadnejad (Narmani et al, ) were developed FA‐PAMAM‐PEG‐5FU‐ 99m Tc in order to imaging and therapeutic goals. In the in vivo study, their synthetic nanocomplex was effectively targeted breast cancer cells (fourfold better than nontargeted complex) in tumor bearing mice ( n = 3 per every group).…”

Section: Polymer‐based Nps In Drug Deliverymentioning

confidence: 99%

“…On the other hand, FR‐γ and FR‐γ′ expression high levels are also related to certain hematopoietic malignancies (Ross et al, ). Thus, cancer selectivity of FA and FA conjugates can be considered as potent approach in NP‐based targeted delivery of anticancer therapeutic agents in cancer diagnosis and therapy (Figure ; Narmani, Yavari, & Mohammadnejad, ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Narmani

Rezvani

Farhood

et al. 2019

Drug Development Research

Self Cite

171

View full text Add to dashboard Cite

Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from Pglycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed-folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR-mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs-based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented. K E Y W O R D Scancer diagnosis and therapy, folic acid, nanoparticles, nanotechnology, targeted drug delivery

show abstract

Section: Polymer‐based Nps In Drug Deliverymentioning

confidence: 99%

Section: Polymer‐based Nps In Drug Deliverymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Narmani

Rezvani

Farhood

et al. 2019

Drug Development Research

Self Cite

171

View full text Add to dashboard Cite

show abstract

“…Nowadays, rapid development of nanotechnology has enabled the development of dendrimer‐based nanohybrids as contrast agents to overcome the severe shortcomings of clinical contrast agents . For instance, functionalized dendrimers have been used to 1) load Au NPs for computed tomography (CT) imaging, 2) chelate gadolinium (III) (Gd(III)) for magnetic resonance (MR) imaging, 3) radiolabel technetium 99m ( 99m Tc) or iodine‐131 ( 131 I) for single‐photon emission computed tomography (SPECT) imaging, and copper 64 ( 64 Cu) for positron emission tomography imaging. For precision‐imaging purposes, it is essential to combine different imaging modalities to achieve complementary physiological and spatial information.…”

Section: Introductionmentioning

confidence: 99%

Targeted Tumor Hypoxia Dual‐Mode CT/MR Imaging and Enhanced Radiation Therapy Using Dendrimer‐Based Nanosensitizers

Fan

Shen

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

The efficacy of radiation therapy (RT) is often limited by the poor response of hypoxia inside most solid tumors. The development of a theranostic nanoplatform for precision‐imaging‐guided sensitized RT for tumor hypoxia is still challenging. Herein, the creation of hypoxia‐targeted dendrimer‐entrapped gold nanoparticles complexed with gadolinium(III) (Gd‐Au DENPs‐Nit) for dual‐mode CT/MR imaging and sensitized RT of hypoxic tumors is reported. In this work, generation 5 poly(amidoamine) dendrimers are partially conjugated with Gd(III) chelator, entrapped with Au nanoparticles, and conjugated with hypoxia‐targeting agent nitroimidazole via a polyethylene glycol linker, and ending with chelation of Gd(III) and conversion of their leftover amine termini to acetamides. The designed dendrimer‐based nanohybrids with 3.2 nm Au cores exhibit an excellent X‐ray attenuation effect, acceptable r1 relaxivity (1.32 mM−1 s−1), and enhanced cellular uptake in hypoxic cancer cells, affording efficient dual‐mode CT/MR imaging of tumor hypoxia. Under X‐ray irradiation, the Gd‐Au DENPs‐Nit nanohybrids can produce reactive oxygen species, promote DNA damage, and prevent DNA repair, facilitating sensitized RT of hypoxic cancer cells in vitro and tumor hypoxia in vivo. The developed hypoxia‐targeted dendrimer‐based nanohybrids may be employed as both contrast agents and nanosensitizers for precision tumor hypoxia imaging and sensitized tumor RT.

show abstract

“…The bands at 2935 cm −1 and 2831 cm −1 correspond to aliphatic C-H stretches. The amide carbonyl absorption (HNC = O) from the PAMAM dendrimer was observed at 1630 cm −1 , while at 1543 cm −1 , the amide N-C stretching was identified [21,22,23,24].…”

Section: Resultsmentioning

confidence: 99%

Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells

et al. 2019

View full text Add to dashboard Cite

The peptide-receptor radionuclide therapy (PRRT) is a successful approach for selectively delivering radiation within tumor sites through specific recognition of radiolabeled peptides by overexpressed receptors on cancer cell surfaces. The efficacy of PRRT could be improved by using polymeric radio- and drug- therapy nanoparticles for a concomitant therapeutic effect on malignant cells. This research aimed to prepare and evaluate, a novel drug and radiation delivery nanosystem based on the 177Lu-labeled polyamidoamine (PAMAM) dendrimer (DN) loaded with paclitaxel (PTX) and functionalized on the surface with the Lys1Lys3(DOTA)-bombesin (BN) peptide for specific targeting to gastrin-releasing peptide receptors (GRPr) overexpressed on breast cancer cells. DN was first conjugated covalently to BN and DOTA (chemical moiety for lutetium-177 complexing) and subsequently loaded with PTX. The characterization by microscopic and spectroscopic techniques, in-vitro drug delivery tests as well as in in-vitro and in-vivo cellular uptake of 177Lu-DOTA-DN(PTX)-BN by T47D breast cancer cells (GRPr-positive), indicated the formation of an improved delivery nanosystem with target-specific recognition by GRPr. Results of the 177Lu-DOTA-DN(PTX)-BN effect on T47D cell viability (1.3%, compared with 10.9% of 177Lu-DOTA-DN-BN and 14.0% of DOTA-DN-(PTX)-BN) demonstrated the concomitant radiotherapeutic and chemotherapeutic properties of the polymeric nanosystem as a potential agent for the treatment of GRPr-positive tumors.

show abstract

Imaging, biodistribution and in vitro study of smart 99mTc-PAMAM G4 dendrimer as novel nano-complex

Cited by 64 publications

References 35 publications

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Targeted Tumor Hypoxia Dual‐Mode CT/MR Imaging and Enhanced Radiation Therapy Using Dendrimer‐Based Nanosensitizers

Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells

Contact Info

Product

Resources

About